Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1103)	7/24/2003 3:59:38 PM
From: Tomato	Read Replies (1) \| Respond to of 1833

Rick, Ever hear back from Ms. CEO? Regards

To: scaram(o)uche who wrote (1103)	8/30/2003 3:07:44 PM
From: Tomato	Read Replies (3) \| Respond to of 1833

I thought I'd try to get some new insights nudged out of someone here.... Anyone care to opine on where KDUS goes from here (and when)? BTW, Rick- did Ms. Paige ever say whether there are any royalties involved in addition to the cash payments of the major pharma? What are the odds that the long (very long) anticipated acquisition takes place in '03? Assuming that there's about $2/sh. in stock and cash, what would the biotech components add per share at this point? Put differently, what are the price targets of readers of this thread? Personally, I sleep well knowing that there's $2 in cash and stock, and figure that's the minimum the stock will fetch (but when?). Then there are the (in)famous tax loss carryovers, the possible royalties, milestone payments...If Paige pulls off an acquisition worthy of Icahn's reputation as a negotiator par excellance, then things could look very rosy.... Of course the biotech index has outperformed KDUS for the last year...but KDUS is more of a value stock than a biotech stock now, so maybe that's comparing apples and oranges.... A penny for your thoughts....